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Introduction: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex autoinflam-
matory disease with substantial morbidity, often characterized by fever, rash, and muscle 
pain, amongst other symptoms. Biologic agents, such as anakinra, have been successfully 
used to treat patients internationally, but their usage in some regions is limited to patients that 
have failed to achieve clinically inactive disease with corticosteroids and conventional 
synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Use of anakinra early in 
the disease course leads to better clinical outcomes; however, longer-term costs for this 
treatment strategy have not been established. This study compares the economic implications 
of first-line versus later-line availability of anakinra for patients with sJIA.
Methods: Data for patients treated with first-line anakinra were identified from a single- 
center, prospective study and compared to a combination of published trial and economic 
evaluation information to facilitate a comparison to later-line anakinra (ie, following corti-
costeroids + csDMARDs). Costs were estimated for product acquisition and medical 
resource utilization (MRU), including planned outpatient visits and unplanned hospital 
admissions. Total costs over a 5-year horizon were compared.
Results: Total 5-year product acquisition cost for the first-line anakinra strategy was 
€24,021, and for later-line anakinra was €20,471. The corresponding MRU costs were 
€19,197 (first-line) versus €25,425 (later-line). Overall 5-year costs (product acquisition 
and MRU) were lower for the first-line strategy (€43,218 versus €45,896).
Conclusion: The use of anakinra for patients with sJIA in the first-line setting is efficacious 
to induce and sustain inactive disease, and the findings of this study show that this treatment 
strategy leads to cost savings through reduced medical expenditure.
Keywords: Still’s disease, systemic juvenile idiopathic arthritis, anakinra, economic 
comparison, treatment strategies, first line
Plain Language Summary
Anakinra, a treatment for patients with systemic juvenile idiopathic arthritis (sJIA), has been 
used in patients with sJIA for over a decade. Different regions treat with anakinra at different 
stages in the treatment pathway. In some regions, anakinra is used as a first-line treatment 
option, whereas in others, its use is reserved for patients who fail to respond to treatment 
with non-steroidal anti-inflammatory drugs (NSAIDs) and conventional synthetic disease- 
modifying antirheumatic drugs (csDMARDs), or, in other words, “later-line” use of anakinra. 
This study presents the first economic comparison of different treatment strategies in sJIA. 
We identified data from a range of different sources and estimated the costs of total drug and 
medical resource use associated with each alternative treatment regimen. We then compared 
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the total costs accrued over a five-year period. The results of our 
analysis show first-line anakinra treatment is associated with cost 
savings versus later-line use, when considered in the context of 
the full cost implications of patient management.
Introduction
Systemic juvenile idiopathic arthritis (sJIA) is a rare, com-
plex autoinflammatory disease, with an incidence of 0.5– 
0.9 per 100,000 children.1–4 It is associated with substan-
tial morbidity, and is usually characterized by spiking 
fever, rash, muscle pain, arthritic symptoms, in addition 
to liver and spleen enlargement.5–7 With an average age of 
diagnosis between 3 and 5 years, children with sJIA have 
reduced quality of life, caused by impaired physical and 
social functioning, which is especially detrimental in 
developing years.8,9
While sJIA is often considered a subtype of juvenile 
idiopathic arthritis (JIA), its systemic nature differentiates 
it from other, more common rheumatic diseases in several 
aspects. It is understood to be a polygenic autoinflamma-
tory disease characterized by an excessive activation of the 
innate immune system and secretion of interleukin-1 (IL- 
1), -6, and -18. It is therefore different to other forms of 
JIA that are considered to be autoimmune where the 
pathology is predominantly driven by the adaptive 
immune system.10 sJIA is also described as the most 
severe and potentially life-threatening disease in the 
group of JIA.10 More recently, sJIA and adult-onset 
Still’s disease (AOSD) have been described as the same 
disease entity with different ages of onset.11
Owing to its systemic nature, sJIA is one of very few 
rheumatic diseases associated with the development of 
macrophage activation syndrome (MAS) – a potentially- 
fatal complication, recognized as the most frequent life- 
threatening complication of Still’s disease.12,13 Therefore, 
in addition to substantial morbidity, sub-optimal manage-
ment of sJIA is associated with an increased risk of 
mortality.
Traditionally, the management of sJIA was concerned 
primarily with reducing the risk of long-term complica-
tions associated with the disease (including issues related 
to long-term steroid use, and the requirement for articular 
surgery), as opposed to achieving a state of clinically- 
inactive disease (CID, or “remission” – that is, an absence 
of disease-related symptoms and normalization of labora-
tory markers). This was a direct consequence of the lack of 
efficacious treatments that had been specifically studied 
within sJIA populations, and so clinical practice 
historically comprised the use of unlicensed treatments 
that had been studied in other rheumatic diseases. These 
unlicensed treatment options for sJIA include non- 
steroidal anti-inflammatory drugs (NSAIDs), corticoster-
oids, and conventional-synthetic disease-modifying anti- 
rheumatic drugs (csDMARDs). Moreover, the only rando-
mized, placebo-controlled trial of methotrexate 
(csDMARD) in patients with sJIA did not demonstrate 
a statistically significant improvement in the systemic fea-
tures of the disease.14
While traditional therapies were able to improve symp-
toms, their mechanistic properties did not allow for 
patients to achieve a state of CID. Following increased 
understanding of the role of IL-1/IL-6 in sJIA, biologic 
DMARDs (bDMARDs) were studied in sJIA populations 
in a number of clinician-led studies.14–17 Anakinra 
(Kineret®, Sobi), an IL-1 receptor antagonist, has been 
used to treat patients with sJIA for over a decade across 
Europe,18 and was licensed for the treatment of Still’s 
disease (including sJIA) in April 2018.19,20 With the avail-
ability of bDMARDs targeting IL-1/IL-6, treatment goals 
shifted from management of symptoms to achieving CID.
Clinical studies have shown that it is possible to 
achieve CID with bDMARDs, though outcomes are parti-
cularly impressive for patients treated with anakinra 
shortly after diagnosis.21 Cytokine blockade early in the 
course of Still’s disease may allow patients to achieve 
remission before the development of chronic, destructive, 
and often therapy-resistant arthritis.20–25
A number of clinical guidelines have been updated to 
reflect the expected benefits associated with earlier use of 
bDMARDs, acknowledging more recent clinical 
studies.11,26,27 Cohorts of sJIA patients in the 
Netherlands and Italy have been treated with first-line 
anakinra, and a majority of patients were shown to achieve 
CID, many of whom were able to discontinue therapy in 
the longer term.21,25,28,29 Earlier use of anakinra has been 
shown to be associated with clinical benefits; however, it 
is important to note that this strategy may have an impact 
on the overall cost of managing patients. To establish its 
cost-effectiveness, a comparison of hypothetical treatment 
pathways (ie, use of anakinra early versus later in the 
treatment pathway) is required.
To our knowledge, no comparison of treatment strate-
gies in sJIA from an economic perspective have been 
previously conducted. This study aimed to formally com-
pare alternative treatment strategies with anakinra (where 
it is available in a first-line versus later line setting) in the 
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management of sJIA to illustrate the differences in 
expected costs.
Materials and Methods
Strategies to be Compared
This study considers a comparison of two treatment 
strategies:
1. First-line anakinra: This strategy is concerned with 
the use of anakinra as soon as possible after diag-
nosis, theoretically prior to the use of any active 
treatment for sJIA (including corticosteroids). This 
strategy is aligned with the latest Single Hub and 
Access point for pediatric Rheumatology in Europe 
(SHARE) treatment guidelines,11 the Dutch 
Pediatrics Association guidelines (Nederlandse 
Vereniging voor Kindergeneeskunde, NVK),26 and 
a number of recent studies.21,25,28,29
2. Later-line anakinra: This strategy involves the use 
of anakinra after the use of NSAIDs, corticoster-
oids, and at least one csDMARD (such as metho-
trexate). Use of anakinra in this setting is aligned 
with the use of anakinra in earlier published studies 
(such as ANAJIS15) and is representative of current 
practice in the UK (per NICE TA238 and TA685 
guidance, and a National Health Service clinical 
commissioning policy).30–32
Evidence Base
Most countries treat sJIA patients based on a national 
policy (including the UK and the Netherlands).26,30,31 
Therefore, it is unlikely that a head-to-head comparison 
of alternative treatment strategies in the same country 
would be possible (eg, comparing strategies where ana-
kinra is available in the first-line setting, versus only being 
available in a later-line setting). Accordingly, data to 
inform both treatment strategies were sought from the 
literature, with the expectation that supporting studies are 
likely to have been conducted in different geographies. 
Where literature was unavailable, information from pub-
lished reports (eg, NICE guidance) were considered, else 
assumptions were made where necessary (which are 
described where applicable throughout).
For patients treated using a first-line anakinra strategy, 
data regarding the duration of treatment and proportion of 
patients that achieve CID were taken from ter Haar et al.21 
This study reports on a population of n=42 patients with 
sJIA treated with anakinra monotherapy according to 
a treat-to-target strategy (before the use of corticosteroids), 
and followed for a median of 5.8 years.21 At 1 year, 76% 
of patients (30/42) had CID and 52% (22/42) had CID off 
medication.21 For those that were followed up to 5 years, 
96% (24/25) had CID, and 72% (18/25) had CID off 
medication.21
In contrast to a first-line treatment strategy, there is no 
equivalent, comprehensive study available to consider the 
costs and outcomes for a later-line anakinra treatment 
strategy. However, tocilizumab (RoActemra®, Roche, an 
IL-6 inhibitor) was previously assessed by the National 
Institute for Health and Care Excellence (NICE) in this 
setting (TA238), which is broadly aligned with the use of 
anakinra for sJIA in a later-line setting.30 Therefore, data 
and assumptions used to inform NICE TA238 were used to 
produce estimated costs for the later-line anakinra setting, 
supported with additional information from the literature 
where needed.
Patients managed with a later-line anakinra strategy 
were assumed to be treated with NSAIDs, corticosteroids, 
and a csDMARD (methotrexate) prior to the initiation of 
bDMARD therapy. Approximately a quarter of patients 
(25.5%) were assumed to have monocyclic disease 
course,33 for which it was assumed possible for patients 
to achieve CID prior to the initiation of bDMARDs. The 
remaining patients were assumed to have chronic disease 
course. For NSAIDs + corticosteroids, it was assumed that 
approximately 30% of monocyclic patients would achieve 
remission within 6 weeks, and for methotrexate, 20% 
would achieve remission within 24 weeks (based on the 
Nordström et al study in AOSD, where it was assumed all 
patients that achieved “remission” had monocyclic disease 
course17).
Approximately 50% of patients (with either monocyc-
lic or chronic disease course) were assumed to achieve 
CID with the first bDMARD used based on the anakinra 
arm of the Nordström et al. study.17 In the base-case 
analysis, it was assumed all patients would currently 
receive tocilizumab as the first choice of biologic therapy 
after csDMARDs (based on its availability as a licensed 
treatment option for sJIA since August 2011). After failure 
on tocilizumab, patients would switch to anakinra. Given 
the lack of head-to-head comparisons between bDMARDs 
in sJIA patients, both products were assumed to have the 
same efficacy.
Discontinuation rates were calibrated based on the 
probabilities of achieving CID, background mortality, 
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and the expectation that nearly all patients will have dis-
continued NSAIDs + corticosteroids and methotrexate 
after 6 and 16 weeks, respectively. To do this, 
a probability of discontinuation per week was estimated 
assuming 95% would discontinue in these time periods. 
For bDMARDs, data from NICE TA238 (tocilizumab for 
sJIA) were taken, in which 12.6% of patients were 
assumed to discontinue bDMARD treatment per year.30 
It was also assumed that some patients would continue 
treatment with bDMARDs with CID. In the base-case 
analysis, this was assumed to be 50%.
Analysis Methodology
A micro-costing analysis was undertaken to estimate the 
total costs related to product acquisition and medical 
resource use (MRU). Product acquisition costs were 
based on estimated durations of treatment from ter Haar 
et al (first-line) and TA238 (later-line).21,30 Unit costs were 
taken from Dutch reference cost sources.34
MRU was assumed to be related to whether or not 
patients still had CID. In the base-case analysis, four cost 
items were considered: outpatient rheumatology appoint-
ments, outpatient hematology appointments, general prac-
titioner (GP) visits, and unplanned hospitalizations. 
Resource use frequencies were sourced from NICE 
TA238, with a revision to the expected number of out-
patient rheumatology appointments per year to align with 
approximately one appointment per month.30 A table of 
parameters included in the analysis is provided in Table 1.
The analysis takes the hypothetical perspective of 
a European cohort of patients, given that no single location 
is expected to consider a blend of both treatment strategies. 
Drug and MRU costs are presented in Euros over a 5-year 
horizon, in line with standard budget impact analysis con-
vention, which are then combined to calculate the overall 
5-year costs associated with each treatment strategy. 
Sensitivity analyses including additional test costs, costs 
associated with MAS and long-term complications of treat-
ment were considered to explore key areas of uncertainty.
Results
Headline Analysis Results
The results of the base-case analysis show that the total 
5-year drug costs for the first-line anakinra strategy were 
€24,021, versus €20,471 for later-line anakinra; and the 
corresponding MRU costs were €19,197 (first-line) versus 
€25,425 (later-line) (Figure 1). Therefore, the overall 
5-year costs (drug acquisition and MRU) were lower for 
the first-line strategy (€43,218 versus €45,896), demon-
strating that first-line anakinra is cost saving (-€2,677) 
relative to a later-line strategy. In other words, while first- 
line anakinra was associated with increased spend related 
to drug acquisition, it led to cost savings associated with 
reduced medical resource use expenditure including, for 
example, a reduction in hospital stays.
Sensitivity Analyses
A number of sensitivity analyses were conducted to further 
explore the likely differences in the costs associated with 
each treatment strategy.
The MRU items included in the base-case analysis 
were selected on the basis of these costs representing the 
majority of direct healthcare costs incurred. However, 
additional costs may be incurred in a real-world setting. 
A sensitivity analysis was conducted to include the costs 
of C-reactive protein and creatinine clearance tests as well 
as public transport for outpatient consultations. By includ-
ing both of these transport-related additional costs, the 
savings associated with first-line anakinra use increased 
further to –€2714.
Patients with active disease are subject to a risk of 
developing MAS, yet these costs were not captured in 
the base-case analysis. To explore the impact of including 
MAS-related costs in the analysis, we considered 
a sensitivity analysis wherein patients with active disease 
had an average of 0.0525 MAS events per year (based on 
a study by Grom et al36). The cost of resolving MAS was 
assumed to be equivalent to a 14-day stay in intensive 
care, including diagnostics and medication. Including 
MAS-related costs, the base-case cost savings increased 
to –€3225.
It is also understood that patients who receive pro-
longed treatment with corticosteroids and/or csDMARDs 
(such as methotrexate) may develop long-term complica-
tions related to treatment.37 In a sensitivity analysis, we 
considered an additional cost of a hospitalization each year 
for 18% of patients (ie, the difference in patients not in 
remission at 5 years, see Table 1) treated with a later-line 
strategy after 5 years for an additional 5 years, as a crude 
exploration of the potential impact of including longer- 
term complications on results. By including this cost, the 
cost savings increased to –€3249.
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Table 1 Economic Analysis Input Parameters
Input Value Reference
Clinical parameters (first-line anakinra) 
These parameters are used to establish which proportion of patients have CAD versus CID over the time frame of the economic analysis, for 
patients managed with first-line anakinra.
CID at 1 year 76% ter Haar et al.21
CID at 3 years 94%
CID at 5 years 96%
CID off treatment at 1 year 52%
CID off treatment at 3 years 71%
CID off treatment at 5 years 72%
Clinical parameters (later-line anakinra) 
These parameters are used to establish which proportion of patients have CAD versus CID over the time frame of the economic analysis, for 
patients managed with later-line anakinra. A multitude of sources is used for this treatment strategy, owing to a lack of data available specifically 
reporting on the experience of sJIA patients managed with later-line anakinra following initial treatment with NSAIDs and csDMARDs.
Monocyclic course 25.5% Grevich and Shenoi33
CID w/ corticosteroids (monocyclic) 30% (in 6 weeks) Assumption
CID w/ methotrexate (monocyclic) 20% (in 24 weeks) Assumption based on Nordström et al.17
CID w/ corticosteroids (chronic) 0% Assumption
CID w/ methotrexate (chronic) 0% Assumption
CID w/ bDMARDs 50% (in 24 weeks) Assumption based on Nordström et al.17
Discontinuation for NSAIDs + 
corticosteroids
95% off by 6 weeks Assumption
Discontinuation for csDMARD ± 
NSAIDs + corticosteroids
95% off by 16 weeks Assumption
Discontinuation for bDMARDs 12.6% per year NICE TA23830
Proportion on bDMARDs with CID 50% Assumption
CID at 5 years 78% Calculation based on input parameters above
Difference in CID at 5 years 18%
Drug costs per week 
These parameters are used to inform drug acquisition cost results. These costs refer to the estimated cost per week.




Annual medical resource use 
These parameters are used to estimate the medical resource utilization associated with patients that have CAD versus CID, noting that in general 
patients with CAD require additional resource.
(Continued)
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Discussion
This study demonstrates the economic implications of 
alternative treatment strategies (first-line versus later- 
line) with anakinra (in other words, either used in the 
first-line setting, or in a refractory setting after failure to 
achieve CID with NSAID, corticosteroid, and 
csDMARD treatment [eg, methotrexate]). The results 
of the analysis demonstrate that first-line anakinra is 
Table 1 (Continued). 
Input Value Reference
Rheumatology (CAD) 12.0 NICE TA238.30 For rheumatology, increased from 10 reported in NICE TA238 to 12 




Rheumatology (CID) 4.0 Assumed 1 appointment every 3 months
GP (CID, on treatment) 3.5 NICE TA23830
GP (CID, off treatment) 0.0 Assumption
Unit costs for medical resource use 
These parameters are used to assign costs based on the expected frequency of use (separated by CAD versus CID, as shown in the preceding 
rows).
Rheumatology or hematology € 101.00 iMTA costing tool:34 Outpatient visit, pediatrics
GP € 33.00 iMTA costing tool:34 General practitioner, standard consultation
Hospitalization € 642.00 iMTA costing tool:34 Nursing day, academic hospital
Abbreviations: bDMARD, biologic disease-modifying anti-rheumatic drug; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; CAD, clinically-active 
disease; CID, clinically-inactive disease; GP, General practitioner; iMTA, Institute for Medical Technology Assessment; NICE, National Institute for Health and Care 
Excellence; NSAID, non-steroidal anti-inflammatory drug; TA, technology appraisal.
Figure 1 Base-case analysis results.
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cost-saving relative to later-line use, which, when con-
sidered in conjunction with the improved clinical out-
comes, gives further justification for the use of anakinra 
earlier in the course of sJIA.
The conclusion reached by the analysis presented may 
be surprising when considering the costs of biologic thera-
pies in other rheumatic diseases. However, it is important 
to acknowledge that anakinra was first granted a marketing 
authorization in March 2002 (for its use in patients with 
rheumatoid arthritis), and has been used in clinical practice 
in the management of Still’s disease for over a decade.20 
As such, the weekly cost of anakinra (€225, based on 
Dutch reference costs, last updated June 2020) is relatively 
low compared with other, more recent bDMARDs, such as 
canakinumab (Ilaris®, Novartis), which has an equivalent 
weekly cost of approximately €2750 (assuming one vial is 
used every 4 weeks, also last updated June 2020).
The clinical evidence in support of using anakinra ear-
lier in the disease course is increasing over time. The 
SHARE guidelines advocate the use of anakinra as early 
as possible in sJIA to capitalize on the potential benefits of 
early IL-1 inhibition.11 A recent study by Pardeo et al also 
demonstrated the probability of achieving CID with ana-
kinra based on the disease duration from onset to start of 
anakinra – 91.9% of patients that started anakinra within 3 
months of disease onset achieved CID off corticosteroids, 
versus 36.8% who started after 3 months of disease 
onset.25 Accordingly, our study provides a timely assess-
ment of the economic implications of earlier versus later 
use of anakinra.
In addition to anakinra, two other bDMARDs are 
licensed for the treatment of sJIA: tocilizumab (an IL-6 
inhibitor) and canakinumab (an IL-1β inhibitor). However, 
unlike anakinra, both of these bDMARDs are only licensed 
for use after previous therapy with NSAIDs and corticoster-
oids, and tocilizumab is not licensed for the treatment of 
AOSD. Anakinra may be used within its licensed indication 
in patients with active systemic features of moderate to high 
disease activity without prior use of NSAIDs and corticos-
teroids. This distinction in the marketing authorization for 
bDMARDs is especially important in consideration of the 
emerging evidence for the role of targeted therapies in Still’s 
disease, where anakinra can be started as soon as practically 
possible following diagnosis.
Economic analyses for sJIA treatments are limited in 
number, which is unsurprising given the rarity of sJIA. 
Our analysis makes use of some information reported in 
NICE TA238 (tocilizumab in sJIA).30 In addition to the 
previous NICE assessment of tocilizumab, Kittiratchakool 
et al recently undertook a cost-effectiveness analysis of 
tocilizumab in refractory sJIA.38 This analysis only con-
siders the potential use of tocilizumab in a relapsed setting, 
due to its availability in Thailand specifically in this set-
ting. Conversely, our comparison considers the use of 
bDMARD therapy either in a refractory setting (ie, after 
NSAID, corticosteroid, and csDMARD treatment) or in 
a first-line setting – a comparison that (to our knowledge) 
has not been previously attempted.
We considered a synthesis of available information to 
compare the alternative treatment strategies. In doing so, 
we aimed to use the best available evidence to explore the 
differences in costs for each strategy, allowing for sensi-
tivity analyses to be conducted concerning the key input 
parameters and associated assumptions. The ability to 
explore a range of sensitivity analyses for key settings 
and assumptions is an important advantage of our analy-
tical approach, given that data available to quantify speci-
fic assumptions are either limited or in some cases not 
available (for example, the proportion of patients that 
achieve sustained CID with csDMARDs in an sJIA 
population).
Key uncertainties relating to lack of comparative data 
may be resolved with further evidence collection, though 
will unavoidably still be subject to various caveats related 
to differences in practices by geography and difficulties in 
enrolling patients within trials of treatments that are 
already routinely available. In particular, the first-line ana-
kinra strategy considered in our economic analysis is 
based on data from a single-center study by ter Haar 
et al, though findings could have been different had the 
study been repeated in other settings or potentially within 
the context of a multi-center study. Therefore, while our 
study makes use of several assumptions to populate these 
missing data, further research and data collection are 
required to obtain a more robust estimate of the true 
costs associated with the management of sJIA.
In addition to the limited data available to inform our 
economic analysis, it is important to acknowledge that 
sJIA is a heterogeneous disease, and response to treatment 
may differ based on various patient characteristics.24,39,40 
These include time since diagnosis, disease subtype or 
severity, and treatment history.24,39–43 Should additional 
data become available in the future, consideration of how 
outcomes compare across different patient subpopulations 
may be of interest from both a clinical and economic 
perspective.
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The full benefits of first-line anakinra are not fully cap-
tured within our analysis, mainly due to the limitations of 
currently-available evidence. Benefits not captured within the 
main analysis include a reduced risk of developing MAS, the 
avoidance of long-run consequences relating to corticosteroid 
and/or csDMARD exposure, and productivity gains resulting 
from patients achieving CID. While we attempted to address 
these in part through sensitivity analysis, these potential 
benefits should also be considered when interpreting the 
results of our analysis. The findings presented within this 
study may be considered a conservative estimate of the 
potential cost savings associated with first-line anakinra.
Conclusions
To our knowledge, this study presents the first economic 
comparison of treatment strategies in sJIA, based on current 
treatment pathways across Europe. There have been no pub-
lished studies of medical management costs in Still’s disease, 
based on whether patients have achieved CID and/or which 
treatment(s) they are currently managed with. The findings of 
the economic comparison illustrate the value of first-line 
anakinra in sJIA, when considered in the context of the full 
costs of patient management.
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